EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, IMCR: Immunocore Holdings Plc ADR

06 Nov 25 17:26
LAST:

31.60

CHANGE:
 0.80		OPEN:
31.08		HIGH:
31.75		ASK:
0.00		VOLUME:
303.8K
CHG(%):
2.58		PREV:
30.80		LOW:
30.50		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
06 Nov 2531.0831.7530.5031.60303.8K
05 Nov 2531.8532.2230.5430.80368.4K
04 Nov 2531.9632.5031.3331.91169.4K
03 Nov 2533.0134.5031.4332.38360.4K
31 Oct 2532.6833.1532.1433.09280.3K
30 Oct 2532.8733.5032.0532.19136.8K
29 Oct 2533.5233.9132.8432.85293.6K
28 Oct 2533.5034.1533.2233.75109.6K
27 Oct 2533.4834.1832.7733.46148.1K
24 Oct 2531.9133.4431.5033.11248.2K

COMPANY PROFILE

Name:Immunocore Holdings Plc ADR
About:Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat advanced cutaneous melanoma and adjuvant uveal melanoma; and brenetafusp that is in Phase 3 clinical trial to treat first-line advanced cutaneous melanoma and in a Phase 1/2 clinical trial in multiple tumor types. In addition, the company's products under development include IMC-R117C (PIWIL-1) that is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, including colorectal cancer; IMC-P115C (PRAME-HLE-A02) that is in Phase 1 clinical trial for patients with tumors that express PRAME; IMC-M113V that is in Phase 1 clinical trials for a potential functional cure in human immunodeficiency virus (HIV); and IMC-I109V that is in Phase 1 clinical trials for a potential functional cure in hepatitis B virus (HBV). Further, it develops IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-S118AI to treat type 1 diabetes; and IMC-U120AI to treat atopic dermatitis. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Sector:Healthcare
Industry:Biotechnology
Address:92 Park Drive, Abingdon, United Kingdom, OX14 4RY
Website:https://www.immunocore.com
CUSIP:45258D105
CIK:0001671927
ISIN:US45258D1054
FIGI:BBG00YYCXFB9

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-31.75 
Forward P/E:-19.35 
PEG Ratio:2.43 
Price to Sales:4.68 
Price to Book:4.29 
Profit Margin:-0.06 
Operating Margin:-0.15 
Return on Assets:-0.02 
Return on Equity:-0.05 
EPS Ratio:-0.41 
Revenue:356.14M 
Shares:50.39M 
Market Cap:1.592B 

TECHNICAL INDICATORS

MA5:31.961.1%
MA10:32.512.9%
MA20:32.743.6%
MA50:33.817.0%
MA100:33.556.2%
MA200:32.031.4%
STO9:21.49
STO14:21.49
RSI14:40.57
WPR14:-74.68
MTM14:-2.35
ROC14:-0.07 
ATR:1.54 
Week High:34.509.2%
Week Low:30.503.6%
Month High:35.0811.0%
Month Low:30.501.4%
Year High:39.3324.5%
Year Low:23.1536.5%
Volatility:11.92